MO
MODD.BO
—
BSE (India)
Healthcare Facilities & Services
Modern Diagnostic & Research Centre Ltd
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
17,7 %
ROE
43,3 %
Net margin
11,5 %
Debt / equity
1,07
Beta
—
52w range
—
Volume
11
Day range
$4,71–$4,90
Prev close
$4,88
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Modern Diagnostic & Research Centre Ltd provides diagnostic and research services in the healthcare sector, primarily generating revenue through laboratory testing and related healthcare services.
Business. Modern Diagnostic & Research Centre Ltd (MODD.BO) is a healthcare services company engaged in diagnostic and research activities within the Healthcare Facilities & Services industry. The firm operates primarily in India, where it is headquartered and listed on the Bombay Stock Exchange. Specific details regarding operating segments and geographic revenue breakdowns are not disclosed.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability→
43,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to MODD.BO. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ2 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Modern Diagnostic & Research Centre Ltd (MODD.BO) is a healthcare services company engaged in diagnostic and research activities within the Healthcare Facilities & Services industry. The firm operates primarily in India, where it is headquartered and listed on the Bombay Stock Exchange. Specific details regarding operating segments and geographic revenue breakdowns are not disclosed.
Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
AI synthesis
GENERATEDModern Diagnostic & Research Centre Ltd maintains a capital structure with a debt-to-equity ratio of 1.07, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.75, suggesting that its current liabilities exceed its current assets. Despite a net income of INR 89.68 million, the company reported negative free cash flow of INR 14,000, primarily due to a significant capital expenditure of INR 131.59 million.
In terms of profitability, the company's return on equity (ROE) is 43.27%, and its return on assets (ROA) is 13.89%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating substantial returns relative to its equity and asset base, which is favorable compared to industry norms.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if the primary segment faces challenges.
The company's growth trajectory is not explicitly outlined in the available data, but the significant capital expenditure indicates a strategic investment in future operations. The outlook for the current fiscal year is not provided, but the company's financial performance suggests a stable position in the market.
The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, indicating a potential liquidity risk. The dilution risk is assessed as low, with no significant dilution potential reported in the data. The company's capital structure and liquidity position suggest that it is managing its financial obligations without immediate dilution pressures.
Recent events and filings do not provide specific details on new developments or strategic initiatives for the company. The absence of recent significant events may indicate a stable but potentially less dynamic business environment for the company.
Key takeaways
- The company has a strong return on equity and return on assets, indicating efficient use of capital.
- The debt-to-equity ratio is moderate, suggesting a balanced capital structure.
- The company's liquidity position is medium, with a current ratio below 1.
- The company's revenue is concentrated in a single segment, which may increase operational risk.
- The company has a significant capital expenditure, indicating investment in future growth.
- The risk of dilution is low, and the company's liquidity position is stable.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$57,39
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$207.3M
Net cashⓘ
-$213.1M
Current ratioⓘ
0.8
Debt / equityⓘ
1.1
ROAⓘ
13.9%
ROEⓘ
43.3%
Cash conversionⓘ
153.0%
CapEx / revenueⓘ
-16.9%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Corporate eventM&A horizon
M&A probabilityconf 5 %
Probability
5 %
Base rate
3 %
Band
—
180-day horizon · target 2027-01-16 · 1,8× base rate
No acquirer candidates identified by the signal model.
Probabilistic model output — not investment advice. · generated 2026-07-20
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin17,7 %Above P75
Net Margin11,5 %Above median
ROE43,3 %Best in class
Capex / Rev-16,9 %Bottom quartile
D/E1,07Bottom quartile
Cash Conv1,53Above median
Corporate actions / M&A
M&A probabilityconf —
Probability
5 %
Base rate
3 %
Band
Moderate
180-day horizon · target 2027-01-16 · 1,8× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 138 266 sh28 grants7 insiders
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,88grant · 2026-06-30
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,88grant · 2026-06-30
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,88grant · 2026-06-30
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,88grant · 2026-06-30
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 62 @ $4,88grant · 2026-06-30
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 250 @ $4,88grant · 2026-06-30
- Chief Operating Officer · Option to purchase common stock → Common StockAcquired 4 674 @ $3,46grant · 2026-05-14
- See Remarks · Option to purchase common stock → Common StockAcquired 11 218 @ $3,46grant · 2026-05-14
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,55grant · 2026-03-31
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,55grant · 2026-03-31
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,55grant · 2026-03-31
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 250 @ $4,55grant · 2026-03-31
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 62 @ $4,55grant · 2026-03-31
- Director · Option to purchase common stock → Common StockAcquired 250 @ $4,55grant · 2026-03-31
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,36grant · 2025-12-31
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,36grant · 2025-12-31
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,36grant · 2025-12-31
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 1 875 @ $0,36grant · 2025-12-31
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 7 500 @ $0,36grant · 2025-12-31
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,36grant · 2025-12-31
- Director · Warrants to purchase Common Stock → Common StockAcquired 30 000 @ $0,45grant · 2025-12-11
- Director · Warrants to purchase Common Stock → Common StockAcquired 11 000 @ $0,45grant · 2025-12-11
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,70grant · 2025-09-30
- Director · Option to purchase common stock → Common StockAcquired 7 500 @ $0,70grant · 2025-09-30
- Director, 10% owner · Option to purchase common stock → Common StockAcquired 7 500 @ $0,70grant · 2025-09-30
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- Modern Diagnostic & Research Centre Ltd Market data — financials · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $04 insiders · last 365d
- Director · Common StockOther 25 · 2026-06-30
- Director · Common stockOther 83 · 2026-06-30
- Director · Common StockOther 110 · 2026-06-30
- Director · Common StockOther 25 · 2026-03-31
- Director · Common stockOther 83 · 2026-03-31
- Director · Common StockOther 103 · 2026-03-31
- Director · Common StockOther 3 125 · 2025-12-31
- Director · Common stockOther 2 500 · 2025-12-31
- Director · Common StockOther 750 · 2025-12-31
- Director · Common StockOther 60 000 · 2025-12-11
- Director · Common StockOther 22 000 · 2025-12-11
- Director · Common StockOther 3 125 · 2025-09-30
- Director · Common StockOther 750 · 2025-09-30
- Director · Common stockOther 2 500 · 2025-09-30
Short positioning
40.8Kfails-to-deliver
as of 2026-03-31 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
MODD.BOCanonical
BSE (India) · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Evidence & claims
From filings & derived data- EPS (basic) (annual): USD-PER-SHARES -12Unknown
- Net income (annual): USD -28.24MUnknown
- Total operating expenses (annual): USD 27.56MUnknown
- Operating cash flow (annual): USD -23.75MUnknown
- Operating income (annual): USD -27.56MUnknown
- R&D expense (annual): USD 19.97MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -12Unknown
- Capex (annual): USD 3.93MUnknown
- Pre-tax income (annual): USD -28.24MUnknown
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -42.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -58.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.74xDerived (calculated)
- Current ratio (FY 2025-12-31): 1.59xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 132.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -15.6%Derived (calculated)
- Total assets (annual): USD 10.26MSEC XBRL filing
- Shareholders' equity (annual): USD 5.88MSEC XBRL filing
- Cash & equivalents (annual): USD 2.94MSEC XBRL filing
- Current liabilities (annual): USD 2.18MSEC XBRL filing
- Current assets (annual): USD 3.47MSEC XBRL filing
- Total liabilities (annual): USD 4.38MSEC XBRL filing
- Shares outstanding (annual): 77.7MSEC XBRL filing
- Operating income (YoY) (2025-03-31 vs 2024-03-31): -8.7%Derived (calculated)
- Operating cash flow (YoY) (2025-03-31 vs 2024-03-31): -12.7%Derived (calculated)
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
2026-07-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-03EVENTQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-30INSIDERFELSHER STEVEN G transacted 25 sh — Director
2026-06-30INSIDERDeSisto Duane M transacted 83 sh — Director
2026-06-30INSIDERVolkart Carmen B transacted 110 sh — Director
2026-06-30INSIDERSheibley Philip Brent acquired 250 sh Option to purchase common stock — Director
2026-06-30INSIDERVos Ellen O'Connor acquired 250 sh Option to purchase common stock — Director
2026-06-30INSIDERFELSHER STEVEN G acquired 250 sh Option to purchase common stock — Director
2026-06-30INSIDERGoldberg Jeff D acquired 250 sh Option to purchase common stock — Director
2026-06-30INSIDERFRANK MORGAN C. acquired 62 sh Option to purchase common stock — Director, 10% owner
2026-06-30INSIDERFRANK MORGAN C. acquired 250 sh Option to purchase common stock — Director, 10% owner
2026-06-26EVENTQ2 2026 earnings (expected) estimated date
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDERInstitutional holding changed
2026-06-21 02:57 UTCHOLDER2 institutional position changes flagged
2026-05-14 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
2026-05-14 00:00 UTCINSIDER2 insider transactions — 2026-05 2 derivative
2026-05-14INSIDERDiPerna Paul acquired 11.2k sh Option to purchase common stock — See Remarks
2026-05-14INSIDERSchmid Kevin acquired 4.7k sh Option to purchase common stock — Chief Operating Officer
2026-03-31 00:00 UTCINSIDER9 insider transactions — 2026-03 6 derivative
2026-03-31 00:00 UTCINSIDER9 insider transactions — 2026-03 6 derivative
2026-03-31INSIDERFELSHER STEVEN G transacted 25 sh — Director
2026-03-31INSIDERDeSisto Duane M transacted 83 sh — Director
2026-03-31INSIDERVolkart Carmen B transacted 103 sh — Director
2026-03-31INSIDERFRANK MORGAN C. acquired 62 sh Option to purchase common stock — Director, 10% owner
2026-03-31INSIDERGoldberg Jeff D acquired 250 sh Option to purchase common stock — Director
2026-03-31INSIDERSheibley Philip Brent acquired 250 sh Option to purchase common stock — Director
2026-03-31INSIDERFELSHER STEVEN G acquired 250 sh Option to purchase common stock — Director
2026-03-31INSIDERFRANK MORGAN C. acquired 250 sh Option to purchase common stock — Director, 10% owner
2026-03-31INSIDERVos Ellen O'Connor acquired 250 sh Option to purchase common stock — Director
Showing the 40 most recent of 69 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage